PL2131845T3 - Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie - Google Patents

Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie

Info

Publication number
PL2131845T3
PL2131845T3 PL08717228T PL08717228T PL2131845T3 PL 2131845 T3 PL2131845 T3 PL 2131845T3 PL 08717228 T PL08717228 T PL 08717228T PL 08717228 T PL08717228 T PL 08717228T PL 2131845 T3 PL2131845 T3 PL 2131845T3
Authority
PL
Poland
Prior art keywords
phenyl
polymorphs
morpholin
isoxazole
ylmethyl
Prior art date
Application number
PL08717228T
Other languages
English (en)
Inventor
Martin James Drysdale
Brian William Dymock
Christoph Krell
Michael Mutz
Holger Petersen
Weijia Zheng
Original Assignee
Novartis Ag
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2131845(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Vernalis R&D Ltd filed Critical Novartis Ag
Publication of PL2131845T3 publication Critical patent/PL2131845T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL08717228T 2007-03-01 2008-02-28 Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie PL2131845T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07103346 2007-03-01
EP08717228A EP2131845B1 (en) 2007-03-01 2008-02-28 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide mesylate, hydrates and polymorphs thereof, and formulations comprising these forms
PCT/EP2008/052443 WO2008104595A1 (en) 2007-03-01 2008-02-28 Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms

Publications (1)

Publication Number Publication Date
PL2131845T3 true PL2131845T3 (pl) 2012-09-28

Family

ID=38134307

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08717228T PL2131845T3 (pl) 2007-03-01 2008-02-28 Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie

Country Status (41)

Country Link
US (3) US8163747B2 (pl)
EP (2) EP2131845B1 (pl)
JP (1) JP2010520176A (pl)
KR (1) KR20090122218A (pl)
CN (2) CN102302500A (pl)
AR (1) AR065519A1 (pl)
AT (1) ATE552836T1 (pl)
AU (1) AU2008220800B2 (pl)
BR (1) BRPI0807992A2 (pl)
CA (1) CA2678043A1 (pl)
CL (1) CL2008000618A1 (pl)
CO (1) CO6210828A2 (pl)
CR (1) CR10989A (pl)
CY (1) CY1113805T1 (pl)
DK (1) DK2131845T3 (pl)
DO (1) DOP2009000209A (pl)
EA (1) EA017075B1 (pl)
EC (1) ECSP099602A (pl)
ES (1) ES2384906T3 (pl)
GE (1) GEP20115309B (pl)
GT (1) GT200900236A (pl)
HK (1) HK1139073A1 (pl)
HR (1) HRP20120535T1 (pl)
IL (1) IL200401A0 (pl)
MA (1) MA31204B1 (pl)
MX (1) MX2009009233A (pl)
NI (1) NI200900161A (pl)
NZ (1) NZ578854A (pl)
PA (1) PA8771101A1 (pl)
PE (1) PE20090166A1 (pl)
PL (1) PL2131845T3 (pl)
PT (1) PT2131845E (pl)
RS (1) RS52351B (pl)
SI (1) SI2131845T1 (pl)
SM (1) SMAP200900080A (pl)
TN (1) TN2009000357A1 (pl)
TW (1) TW200844102A (pl)
UA (1) UA101950C2 (pl)
UY (1) UY30943A1 (pl)
WO (1) WO2008104595A1 (pl)
ZA (1) ZA200905417B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
WO2010060854A1 (en) 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
US9061016B2 (en) * 2010-01-21 2015-06-23 Aprea Ab Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
WO2011102660A2 (en) * 2010-02-17 2011-08-25 Ildong Pharm Co., Ltd. A novel 5-membered heterocycle derivatives and manufacturing process thereof
KR20120031854A (ko) 2010-09-27 2012-04-04 한국전자통신연구원 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4921162B2 (ja) * 2003-02-11 2012-04-25 ヴァーナリス（ケンブリッジ）リミテッド 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類
US20060070405A1 (en) * 2004-10-06 2006-04-06 Anheuser-Busch, Inc. Method for the production of amber glass with reduced sulfur-containing emissions
AU2008216327A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of LBH589 with other therapeutic agents for treating cancer
WO2010069458A1 (de) 2008-12-17 2010-06-24 Merck Patent Gmbh Hexahalochromat(lll)-komplexe

Also Published As

Publication number Publication date
CO6210828A2 (es) 2010-10-20
EP2545921A2 (en) 2013-01-16
CY1113805T1 (el) 2016-07-27
KR20090122218A (ko) 2009-11-26
US20130296556A1 (en) 2013-11-07
AR065519A1 (es) 2009-06-10
TN2009000357A1 (en) 2010-12-31
NZ578854A (en) 2012-03-30
PA8771101A1 (es) 2009-02-09
EP2131845A1 (en) 2009-12-16
SMAP200900080A (it) 2010-01-19
TW200844102A (en) 2008-11-16
CR10989A (es) 2010-03-01
ES2384906T3 (es) 2012-07-13
US8163747B2 (en) 2012-04-24
CL2008000618A1 (es) 2008-09-12
ECSP099602A (es) 2009-12-28
UA101950C2 (ru) 2013-05-27
HK1139073A1 (pl) 2010-09-10
DK2131845T3 (da) 2012-07-16
JP2010520176A (ja) 2010-06-10
EA017075B1 (ru) 2012-09-28
AU2008220800B2 (en) 2012-02-16
CA2678043A1 (en) 2008-09-04
EP2131845B1 (en) 2012-04-11
PT2131845E (pt) 2012-07-10
MA31204B1 (fr) 2010-02-01
UY30943A1 (es) 2008-10-31
ZA200905417B (en) 2010-05-26
MX2009009233A (es) 2010-06-02
US20120172592A1 (en) 2012-07-05
EA200901141A1 (ru) 2010-04-30
US20100093732A1 (en) 2010-04-15
IL200401A0 (en) 2010-04-29
US8487095B2 (en) 2013-07-16
ATE552836T1 (de) 2012-04-15
GEP20115309B (en) 2011-10-25
EP2545921A3 (en) 2013-04-10
SI2131845T1 (sl) 2013-02-28
HRP20120535T1 (hr) 2012-07-31
AU2008220800A1 (en) 2008-09-04
WO2008104595A1 (en) 2008-09-04
RS52351B (en) 2012-12-31
BRPI0807992A2 (pt) 2014-06-17
DOP2009000209A (es) 2009-09-15
CN101636162A (zh) 2010-01-27
NI200900161A (es) 2010-07-27
CN102302500A (zh) 2012-01-04
GT200900236A (es) 2011-09-14
PE20090166A1 (es) 2009-03-14

Similar Documents

Publication Publication Date Title
PL2131845T3 (pl) Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
SI2217578T1 (sl) (1,2,4)triazolo(1,5-a)piridinske in (1,2,4)triazolo(1,5-c)pirimidinske spojine in njihova uporaba
EP2285789A4 (en) NEW SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES
ZA200804762B (en) 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
HK1121381A1 (en) Levodopa prodrug mesylate, compositions thereof, and uses thereof
MA28995B1 (fr) Composition immunogene
IL195511A0 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]
EP2114352A4 (en) LIPSTICK ON GELBASIS WITH IMPROVED RHEOLOGY
IL197161A (en) Derivatives 4- (n-azacycloalkyl) anilides Preparations containing and using them
IL202826A0 (en) New compounds and their uses 708
IL202073A0 (en) Substituted oxazolidinones and the use thereof
EP1954685A4 (en) FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
EP1959959A4 (en) MORPHOLIN-CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS
EP2421528A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES
EP1726638A4 (en) NEW BACTERIUM OF LACTIC ACID
EP2040698A4 (en) OXIM CONNECTIONS AND ITS USE
EP1889829A4 (en) NON-STEROIDIAN ANDROGEN RECEPTOR REGULATORS, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITION AND USES THEREOF
ZA200904187B (en) Novel gene disruptions, compositions and methods relating thereto
EP2279179A4 (en) PHENYL-PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE THEREOF
EP1995235A4 (en) NOVEL 1,3,5-TRIS (DIARYLAMINO) BENZENES AND THEIR USE
EP2028938A4 (en) 3,4-DISUBSTITUTED CUMARIN AND CHINOLINE COMPOUNDS
GB2452696B (en) 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
ZA200708818B (en) Antibacterial 5,5-disubstituted 3,3-dialkoxy-2,2-dihydroxy-1,1-biphenyl compounds and related methods
IL199239A0 (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-